Hims & Hers Health

Hims & Hers Health, Inc.

Company type	Public
Industry	Telehealth, Personal care, Online pharmacy
Founded	2017
Founder	Jack Abraham, Andrew Dudum, Hilary Coles
Headquarters	San Francisco , United States
Area served	United States, United Kingdom
Products	Prescription drugs, over-the-counter items, personal wellness products, mental health services

Hims & Hers Health, Inc. is a U.S.-based telehealth enterprise established in 2017 that provides prescription drugs, over-the-counter items, and personal wellness products. The business follows a direct-to-consumer approach, enabling clients to consult with licensed medical professionals online and purchase treatments directly through its digital platform. Its offerings encompass health solutions tailored for both men and women, including services focused on mental wellness.

Founding, growth, and public listing

Hims Inc. was launched in 2017 by Jack Abraham, Andrew Dudum, and Hilary Coles as a venture within the Atomic Labs portfolio. In January 2019, the company secured $100 million during a Series C funding round, reaching a valuation of $1 billion. That same month marked its expansion into the United Kingdom, where it adjusted its product lineup to meet European regulatory standards.

Public listing

In October 2020, Hims collaborated with Oaktree Capital Management to become a publicly traded entity through a blank check company, resulting in a valuation of $1.6 billion. Following this transition, the firm was rebranded as Hims & Hers Health, Inc. The deal finalized in January 2021, with Hims commencing trading on the New York Stock Exchange.

Offerings and product range

The company's initial portfolio included erectile dysfunction remedies such as sildenafil, alongside hair care products like minoxidil, biotin supplements, and DHT-inhibiting shampoos. In 2018, it introduced Hers, a line dedicated to women’s health featuring items like birth control pills and flibanserin. By 2020, Hims broadened its scope to incorporate mental health support by launching anonymous group therapy sessions.

In 2024, Hims incorporated compounded GLP-1 injections aimed at weight management, emphasizing affordability and accessibility compared to branded alternatives; however, these compounded formulations are not subject to FDA safety evaluation. By 2025, the collaboration with corporate partner Novo Nordisk concluded, leading to the discontinuation of the GLP-1 product offerings.